diabetes treatment

Novo Nordisk Licenses Zealand’s Diabetes Treatment

Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable diabetes treatment.

Sanofi and MannKind Enter Global Licensing Agreement for Afrezza Insulin

Novo Nordisk Launches Diabetes Drug in Germany After Rethink

U.S. Court Fines Takeda, Lilly $9 billion Over Diabetes Drug Safety

Bayer to Spend €100 Million on Chinese Pharma Packaging Upgrade

Novo Nordisk Sees Chance of U.S. Tresiba Launch Before Rivals

Gene Mutations for Type 2 Diabetes Discovered

Roche Decides Against Selling Diabetes Device Unit

Sanofi Steps up Diabetes Drive as Rivals Raise the Stakes

FDA Panel Votes to Relax Avandia Restrictions

Eli Lilly Broadens Diabetes Offer

Sanofi to Step Up Development of New Diabetes Device

U.S. Launch of Novo's New Insulin Faces Long Delay

Novo Hikes Forecasts on Hopes for New Blockbuster Drug

Roche Open to Gene-Sequencing Acquisition

Bayer Diabetes Unit Sale Unlikely

Top Medical Innovations Address Headache, Diabetes, Cancer

AstraZeneca Buys Equal Say over Amylin Drugs

AstraZeneca Hungry to Refill Medicine Cabinet